A recent survey conducted by Magnolia Market Access provides insight directly from insurers, revealing in no uncertain terms that insurers plan to restrict coverage in Part D because of the Inflation Reduction Act (IRA). When assessing the law, the negative impact it is having on access to medicines cannot be overlooked.
Here’s what you should know:
- 89% of insurers plan to increase utilization management tools (like prior approval requirements and fail first policies) and pare down formularies
- 78% of insurers expect to create more stringent utilization management for new medicines
- 83% of insurers plan to increase the number of medicines excluded from their formularies
- 78% of insurers plan to decrease the number of therapeutic options in classes with medicines selected for price setting
A survey conducted by Clarivate Consulting Services had similar findings: Insurers are consistently clear that they plan to restrict access as the IRA changes are implemented. And we’re already seeing it happen with fewer Part D plans being offered in 2024 than in previous years.
The IRA is just beginning to go into effect, but it is already resulting in significant unintended consequences for Medicare beneficiaries. Seniors could experience higher costs, fewer options and disruptions in their health care coverage because the IRA failed to rein in abusive insurer and PBM practices that limit patients’ access to care.
Congress and the administration must act soon to address these issues and protect seniors’ access to essential medicines.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
What AARP isn’t telling seniors about MFN
Policymakers should improve patient access and reject price controls
CMS proposal could discourage patient-centered innovation
Nearly 1 in 4 patients initially denied access to IRA medicines
New survey: Insurers confirm IRA will reduce patient treatment options
Government Price Setting
Medicare
Part D
New survey: Insurers confirm IRA will reduce patient treatment options
New survey: Insurers confirm IRA will reduce patient treatment options